0001567264
false
0001567264
2023-11-13
2023-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 13, 2023
Intensity Therapeutics, Inc.
(Exact name of Registrant as Specified in Its
Charter)
Delaware |
|
001-41109 |
|
46-1488089 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1 Enterprise Drive, Suite 430
Shelton, CT |
|
06484-4779 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
(203) 221-7381
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instructions A.2. below):
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class: |
|
Trading Symbol(s): |
|
Name of Exchange on Which Registered: |
Common Stock, $0.0001 par value per share |
|
INTS |
|
The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 Results of Operations and Financial Condition.
On
November 13, 2023, Intensity Therapeutics, Inc. (the “Company”) released its financial results for the quarter
ended September 30, 2023. A copy of the Company’s press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein
by reference.
The information
in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities
Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS
Comments in this Current Report on Form 8-K and
in the exhibit attached hereto contain certain forward-looking statements within the meaning of Section 27A of the Securities Act and
Section 21E of the Exchange Act, which are based on management’s good faith expectations and beliefs concerning future developments.
Actual results may differ materially from these expectations as a result of many factors. These factors include, but are not limited to,
the risks and uncertainties described in the “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements”
sections of the Company’s prospectus, dated June 29, 2023 and filed on June 30, 2023 pursuant to Rule 424(b) under the Securities
Act relating to the Company’s Registration Statement on Form S-1 (File No. 333-260565). The Company does not undertake any obligation
to update such forward-looking statements. All market and industry data are based on Company estimates.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 13, 2023
|
Intensity Therapeutics, Inc. |
|
|
|
|
By: |
/s/ Lewis H. Bender |
|
|
Name: |
Lewis H. Bender |
|
|
Title: |
Chief Executive Officer |
[Signature Page to the Form 8-K]
2
Exhibit 99.1
Intensity Therapeutics Reports Third Quarter
Financial Results and Provides Corporate Update
Presented positive Phase 1/2 clinical data for
INT230-6 in patients with refractory soft tissue sarcoma at Connective Tissue Oncology Society (“CTOS”), demonstrating 93%
disease control rate in patients on monotherapy and survival extension of nearly 15 months vs. synthetic control group
Received Orphan Drug Designation for the three
components of INT230-6 for the treatment of soft tissue sarcoma
Closed upsized IPO and full exercise of over-allotment
option for $20.2 million in net proceeds
On track to file IND for Phase 3 study of INT230-6
in soft tissue sarcoma and to report additional Phase 2 INVICIBLE study results for presurgical breast cancer by end of 2023
SHELTON,
Conn., November 13, 2023 – Intensity Therapeutics, Inc. (Nasdaq: INTS), a late-stage biotechnology company that applies
novel engineered chemistry to discover and develop proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors
and increase immune system recognition of cancers, today reported financial results for the third quarter ended September 30, 2023, and
provided a corporate update.
“Metastatic soft
tissue sarcoma continues to plague cancer patients who have poor survival outcomes and insufficient therapeutic options. The positive
overall survival and disease control rate data from our Phase 1/2 clinical trial of INT230-6 positions our lead candidate as a potential
much needed reprieve, keeping the drug inside the tumor while sparing the body of toxicity. We expect to file an IND for a Phase 3 study
of INT230-6 in soft tissue sarcoma by the end of 2023 and look forward to progressing this study,” said Lewis H. Bender, President
and Chief Executive Officer of Intensity.
Mr. Bender added: “To
continue the momentum built from our successful upsized IPO in July, we also look forward to reporting additional results from our Phase
2 INVINCIBLE study in presurgical breast cancer at a medical meeting and finalizing the study design and protocol for a Phase 2/3 program
in presurgical breast cancer before year end. I am pleased with our pace of progress to advance the clinical development of INT230-6 and
am strongly encouraged by data to date, which reinforces the potential of INT230-6 to shift the treatment paradigm of cancer.”
Recent Company Highlights
| ● | Presented Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective
Tissue Oncology Society (CTOS). In November, the Company presented positive data from its ongoing Phase 1/2 clinical trial of INT230-6
at the CTOS annual meeting. The data presented demonstrated a strong disease control rate of 93% for subjects in the monotherapy arm while
also extending survival in subjects by nearly 15 months when compared to a synthetic control group. INT230-6 was found to be generally
safe and well tolerated with the majority of treatment-emergent adverse events being grade 1 or 2. |
| ● | Received Orphan Drug Designation for Components of INT230-6 for the Treatment of Soft Tissue
Sarcoma. In September, Intensity was granted orphan drug designation (ODD) by the US Food and Drug Administration for three active
moieties comprising its lead candidate INT230-6: cisplatin, vinblastine sulfate, and the diffusion enhancer SHAO-FA (8-((2-hydroxybenzoyl)
amino)octanoate). |
| ● | Completed Upsized Initial Public Offering (IPO) with Full Exercise of the Over-Allotment Option.
In July, Intensity announced that it had closed its IPO with the full exercise of its over-allotment option. Intensity received a total
of $20.2 million in net proceeds from the transaction, providing sufficient cash and cash equivalents to fund operations into the second
half of 2025. |
Anticipated Near-Term Milestones
| ● | Report additional results from the Phase 2 INVINCIBLE study in presurgical breast cancer at a medical
meeting in 4Q 2023 |
| ● | File an Investigational New Drug (IND) application for a Phase 3 study of INT230-6 in soft tissue sarcoma
in 4Q 2023 |
| ● | Finalize the study design for a Phase 2/3 program in presurgical breast cancer in 4Q 2023 |
Third Quarter 2023 Financial Highlights
Research and Development (R&D) Expenses
were $1.4 million for the three months ended September 30, 2023, as compared to $1.2 million for the same period last year. The increase
is due to ongoing Phase 3 IT-03 in sarcoma and phase 2/3 IT-04 in presurgical breast cancer, which will continue to incur planning, multiple
regulatory filing, manufacturing, study initiation and trial preparation costs in 2023.
General and Administrative (G&A) Expenses
were $1.1 million for the three months ended September 30, 2023, as compared to $0.6 million for the same period in 2022. The increase
is primarily due to the costs of operating as a public company. The accounting services and legal costs related to the IPO in 2023 were
charged directly to the equity section of the balance sheet as a reduction of additional paid in capital.
Interest Expense for the three months ended
September 30, 2023, were $0 as compared to $15,123 for the three months ended September 30, 2022. The decrease is due to the convertible
notes and accrued interest being converted to common stock at the time of the IPO.
Net Operating Loss for the third quarter
ended September 30, 2023, was $2.3 million as compared to $1.8 million for the three months ended September 30, 2022.
Cash, Cash Equivalents and Marketable Securities
as of September 30, 2023, were approximately $15.6 million. The Company expects to have sufficient cash to fund current operations into
the second half of 2025.
About INT230-6
INT230-6, Intensity’s lead proprietary investigational
product candidate, is designed for direct intratumoral injection. INT230-6 was discovered using Intensity’s proprietary DfuseRx℠
technology platform. The drug is composed of two proven, potent anti-cancer agents, cisplatin and vinblastine, and a penetration enhancer
molecule (SHAO) that helps disperse potent cytotoxic drugs throughout tumors for diffusion into cancer cells. These agents remain in the
tumor resulting in a favorable safety profile. In addition to local disease control, direct killing of the tumor by INT230-6 releases
a bolus of neoantigens specific to the patient’s malignancy, leading to engagement of the immune system and systemic anti-tumor effects.
Importantly, these effects are mediated without immunosuppression that so often occurs with systemic chemotherapy.
About Intensity Therapeutics’ Clinical Studies
INT230-6 has completed enrollment of over 200
patients in two phase 2 and phase 1 dose escalation clinical trials (NCT03058289 and NCT04781725) with various advanced solid tumors;
IT-01 in metastatic disease, and IT-02 the INVINCIBLE study, in presurgical breast cancer. The Company has a clinical collaboration agreement
with Merck Sharpe & Dohme (Merck) to evaluate the combination of INT230-6, Intensity’s lead product candidate, and KEYTRUDA® (pembrolizumab),
Merck’s anti-PD-1 (programmed death receptor-1) therapy, in patients with advanced pancreatic, colon, squamous cell and bile duct malignancies.
The Company also has a clinical collaboration agreement with Bristol-Myers Squibb to evaluate the combination INT230-6 with Bristol-Myers
Squibb’s anti-CTLA-4 antibody, ipilimumab, in patients with advanced liver, breast and sarcoma cancers. Intensity managed the individual
combination arms separately with each respective partner via a joint development committee. The Company also executed agreements with
the Ottawa Hospital Research Institute (OHRI) and the Ontario Institute of Cancer Research (OICR) to study INT230-6 in the INVINCIBLE
study, a randomized controlled neoadjuvant phase 2 study in women with early-stage breast cancer. Near-term, Intensity expects to file
an Investigational New Drug (IND) application for a Phase 3 study of INT230-6 in soft tissue sarcoma as well as finalizing the study design
and protocol for a Phase 2/3 program in presurgical breast cancer.
About Intensity
Therapeutics
Intensity Therapeutics
is a late-stage biotechnology company that applies novel engineered chemistry to turn “cold” tumors “hot” by enabling
its aqueous cytotoxic-containing drug product, INT230-6, to mix and saturate the dense, high-fat pressurized environment of the tumor.
As a result of the saturation, Intensity’s clinical trials have demonstrated the ability if INT230-6 to kill tumors and elicit an
adaptive immune response within days of injection, representing a truly novel approach to cancer cell death that holds the potential to
shift the treatment paradigm and turn many deadly cancers into chronic diseases. For more information about the Company, including publications,
papers and posters about its novel approach to cancer therapeutics, visit www.intensitytherapeutics.com.
Forward-Looking
Statements
Certain statements in this press release may constitute
“forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended
to date. These statements include, but are not limited to, statements relating to the expected future plans, development activities, projected
milestones, business activities or results. We have based these forward-looking statements on our current expectations and projections
about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed
in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include:
the risk that the anticipated milestones may be delayed or not occur or be changed, as well as other risks described in the section entitled
“Risk Factors” in the Company’s SEC filings, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned
not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s
current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and
expressly disclaims any duty to update the information contained in this press release except as required by law.
Investor Relations Contact:
Argot Partners
Jonathan Nugent
Intensity@argotpartners.com
Media Contact:
Argot Partners
David Rosen
david.rosen@argotpartners.com
Intensity Therapeutics, Inc.
Condensed Statement of Operations
(Unaudited)
| |
Three Months Ended | | |
Nine Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Operating expenses: | |
| | |
| | |
| | |
| |
Research and development costs | |
$ | 1,351,766 | | |
$ | 1,160,737 | | |
$ | 2,984,752 | | |
$ | 4,241,203 | |
General and administrative costs | |
| 1,138,748 | | |
| 607,113 | | |
| 1,981,594 | | |
| 1,834,966 | |
Total operating expenses | |
| 2,490,514 | | |
| 1,767,850 | | |
| 4,966,346 | | |
| 6,076,169 | |
Loss from operations | |
| (2,490,514 | ) | |
| (1,767,850 | ) | |
| (4,966,346 | ) | |
| (6,076,169 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense): | |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 147,539 | | |
| 988 | | |
| 148,026 | | |
| 1,844 | |
Interest expense | |
| - | | |
| (15,123 | ) | |
| (305,161 | ) | |
| (44,877 | ) |
Loss on debt extinguishment | |
| - | | |
| - | | |
| (2,261,581 | ) | |
| - | |
Other | |
| 13,230 | | |
| 7,118 | | |
| 18,304 | | |
| 47,646 | |
Net loss | |
$ | (2,329,745 | ) | |
$ | (1,774,867 | ) | |
$ | (7,366,758 | ) | |
$ | (6,071,556 | ) |
| |
| | | |
| | | |
| | | |
| | |
Preferred stock deemed dividend | |
| - | | |
| - | | |
| (1,323,535 | ) | |
| - | |
| |
| | | |
| | | |
| | | |
| | |
Net loss attributable to common stockholders | |
$ | (2,329,745 | ) | |
$ | (1,774,867 | ) | |
$ | (8,690,293 | ) | |
$ | (6,071,556 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss per share, basic and diluted | |
$ | (0.17 | ) | |
$ | (0.52 | ) | |
$ | (1.26 | ) | |
$ | (1.78 | ) |
Weighted average number of shares of common stock, basic and diluted. | |
| 13,660,627 | | |
| 3,410,103 | | |
| 6,899,984 | | |
| 3,410,103 | |
Intensity Therapeutics, Inc.
Condensed Balance Sheets
(Unaudited)
| |
September 30, 2023 | | |
December 31, 2022 | |
| |
(unaudited) | | |
(audited) | |
ASSETS | |
| | |
| |
Current assets: | |
| | |
| |
Cash and cash equivalents | |
$ | 6,693,825 | | |
$ | 1,311,877 | |
Marketable debt securities | |
| 8,955,316 | | |
| - | |
Prepaid expenses | |
| 971,239 | | |
| 62,924 | |
Other current assets | |
| 14,366 | | |
| 75,535 | |
Total current assets | |
| 16,634,746 | | |
| 1,450,336 | |
Right-of-use asset, net | |
| 152,605 | | |
| 139,089 | |
Other assets | |
| 28,438 | | |
| 167,738 | |
Total assets | |
$ | 16,815,789 | | |
$ | 1,757,163 | |
| |
| | | |
| | |
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIENCY) | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 358,404 | | |
$ | 603,176 | |
Accrued expenses | |
| 355,006 | | |
| 1,723,400 | |
Current lease liability | |
| 10,556 | | |
| 143,221 | |
Convertible note and accrued interest | |
| - | | |
| 4,348,548 | |
Total current liabilities | |
| 723,966 | | |
| 6,818,345 | |
Long-term lease liability | |
| 144,891 | | |
| - | |
Related party deposit | |
| 36,000 | | |
| 36,000 | |
Total liabilities | |
| 904,857 | | |
| 6,854,345 | |
Series A redeemable convertible preferred stock, par value $.0001. Authorized, issued, and outstanding shares of none and 5,000,000 as of September 30, 2023 and December 31, 2022, respectively. | |
| - | | |
| 10,000,000 | |
| |
| | | |
| | |
STOCKHOLDERS’ EQUITY (DEFICIENCY) | |
| | | |
| | |
| |
| | | |
| | |
Authorized preferred stock is 15,000,000 shares as of September 30, 2023. None issued or outstanding as of September 30, 2023. | |
| | | |
| | |
| |
| | | |
| | |
Series B convertible preferred stock, par value $.0001. Authorized, issued, and outstanding shares of none and 1,449,113 as of September 30, 2023 and December 31, 2022, respectively. | |
| - | | |
| 145 | |
| |
| | | |
| | |
Series C convertible preferred stock, par value $.0001.
Authorized, issued, and outstanding shares of none and 1,800,606 as of September 30, 2023 and December 31, 2022, respectively. | |
| - | | |
| 180 | |
| |
| | | |
| | |
Common stock, par value $.0001. Authorized shares of 135,000,000 and 50,000,000 as of September 30, 2023 and December 31, 2022, respectively. Issued and outstanding shares of 13,709,377 and 3,410,103 as of September 30, 2023 and December 31, 2022, respectively. | |
| 1,371 | | |
| 341 | |
Additional paid-in capital | |
| 63,252,862 | | |
| 23,555,160 | |
Accumulated deficit | |
| (47,343,301 | ) | |
| (38,653,008 | ) |
Total stockholders’ equity (deficiency) | |
| 15,910,932 | | |
| (15,097,182 | ) |
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficiency) | |
$ | 16,815,789 | | |
$ | 1,757,163 | |
6
v3.23.3
Cover
|
Nov. 13, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 13, 2023
|
Entity File Number |
001-41109
|
Entity Registrant Name |
Intensity Therapeutics, Inc.
|
Entity Central Index Key |
0001567264
|
Entity Tax Identification Number |
46-1488089
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
1 Enterprise Drive
|
Entity Address, Address Line Two |
Suite 430
|
Entity Address, City or Town |
Shelton
|
Entity Address, State or Province |
CT
|
Entity Address, Postal Zip Code |
06484-4779
|
City Area Code |
203
|
Local Phone Number |
221-7381
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Stock, $0.0001 par value per share
|
Trading Symbol |
INTS
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
true
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Intesity Therapeutics (NASDAQ:INTS)
Historical Stock Chart
From May 2024 to Jun 2024
Intesity Therapeutics (NASDAQ:INTS)
Historical Stock Chart
From Jun 2023 to Jun 2024